Binkow & Goldberg LLP reminds investors of Regado
Biosciences, Inc. ("Regado" or the "Company") (NASDAQ:RGDO) that all
purchasers of Regado securities pursuant and/or traceable to the
Company's Registration Statement and Prospectus issued in connection
with the Company's initial public offering on or about August 21, 2013,
or on the open market between August 22, 2013 and July 2, 2014,
inclusive (the "Class Period"), have until September 8, 2014, to file a
motion to be appointed as lead plaintiff in the shareholder lawsuit.
Regado is a biopharmaceutical company, focused on the discovery and
development of antithrombotic drug systems for acute and sub-acute
cardiovascular and other indications. The Company's lead prouct
candidate, Revolixys™ Kit, is an anticoagulant for use in patients with
a wide variety of acute coronary syndromes. The Complaint
alleges that defendants made false and misleading statements or failed
to disclose that: (1) the administration of Revolixys presented a
significant risk of severe allergic reaction, which substantially
undermined Revolixys' potential to become the new standard of care for
anticoagulation therapy for patients undergoing cardiovascular
procedures such as percutaneous coronary intervention ("PCI") to open or
widen obstructed coronary arteries; and (2) the Company's positive
statements about Revolixys' clinical development and potential to become
the standard of care for anticoagulation therapy for patients undergoing
PCI and other cardiovascular procedures, were materially false and
misleading or lacked a reasonable basis.
If you are a member of the Class described above, you may move the Court
no later than September 8, 2014, to serve as lead plaintiff; however,
you must meet certain legal requirements. To be a member of the Class,
you need not take any action at this time; you may retain counsel of
your choice or take no action and remain an absent member of the Class.
If you wish to learn more about this action or have any questions
concerning this announcement or your rights or interests with respect to
these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow
& Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, by toll-free telephone at (888) 773-9224 or by
telephone at (310) 201-9150, by e-mail to email@example.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To NFVZone's Homepage ]